Clinical Overview

Folliculitis decalvans (FD) is a suppurative scarring alopecia characterized by chronic purulent inflammation of hair follicles leading to permanent hair loss through follicular destruction and scarring. This rare condition accounts for 1-3% of scarring alopecias and predominantly affects men with male-to-female ratio of 4:1. The disease is progressive without treatment, causing confluent areas of baldness with characteristic violaceous erythema and pustulation. Early recognition and aggressive antimicrobial and anti-inflammatory therapy are essential to arrest disease progression before extensive fibrosis and baldness develop.

Epidemiology

Folliculitis decalvans is rare with estimated prevalence of less than 0.001% in the general population. The condition predominantly affects men aged 20-50 years, though women and children may be affected. No clear racial predilection is documented, though some series suggest higher prevalence in certain populations. The condition is often sporadic but familial clustering has been reported, suggesting possible genetic predisposition. Geographic variation exists without clear explanation. The disease is not contagious despite its suppurative nature.

Pathophysiology

Folliculitis decalvans involves chronic suppurative inflammation of hair follicles with bacterial colonization and destruction. The precise trigger is unknown but likely involves: (1) bacterial infection (Staphylococcus aureus is commonly isolated from cultures), (2) follicular obstruction with sebum accumulation, (3) immune dysfunction or abnormal inflammatory response to bacterial antigens, and (4) genetic predisposition to follicle-directed inflammation. Histologically, severe neutrophilic infiltration around follicles is seen, accompanied by abscess formation, follicular destruction, and eventual fibrosis. The inflammatory cascade causes permanent damage to follicular stem cells in the bulge region, explaining irreversible nature of the alopecia. Some cases may represent a continuum with folliculitis keloidalis nuchae, a related condition affecting the nape of the neck with similar follicular destruction.

Clinical Presentation

Folliculitis decalvans typically presents with recurrent pustules, follicular crusting, and erosions on the scalp, often concentrated on the vertex and parietal areas. Patients experience repeated cycles of pustule formation, drainage of purulent material, and crusting. The scalp appears inflamed with violaceous erythema surrounding affected follicles. Progressive scarring results in permanent alopecia with characteristic appearance: bald scalp with tufts of remaining hair at the margin of active disease, and violaceous erythema marking areas of recent activity. Patients report pruritus, pain, and in some cases purulent drainage from pustules. Lymphadenopathy (enlargement of cervical or occipital lymph nodes) may be present reflecting systemic response to chronic infection. The disease progresses slowly in some patients over years while others show rapid progression causing extensive baldness within months.

Diagnosis

Diagnosis requires clinical presentation combined with bacterial culture and scalp biopsy. Bacterial culture from pustule contents typically yields Staphylococcus aureus, though other bacteria may be isolated. Susceptibility testing determines optimal antibiotic selection. Dermoscopy shows pustules, erythema, and follicular orifices with yellow or brown scale/crust. Scalp biopsy reveals severe neutrophilic infiltration around follicles with abscesses, follicular destruction, and fibrosis. Unlike lymphocyte-predominant infiltrates in lichen planopilaris or lupus erythematosus, FD shows predominantly neutrophilic inflammation, helping distinguish the conditions. Culture of biopsy material may identify causative organisms. Importantly, negative bacterial culture does not exclude FD—some cases may represent culture-negative folliculitis or altered inflammatory response.

Treatment Algorithm

Treatment combines antimicrobial therapy to address bacterial colonization with anti-inflammatory agents to suppress follicular inflammation. Long-term therapy is typically necessary to achieve disease control.

First-line antimicrobial therapy includes oral antibiotic targeting Staphylococcus aureus. Amoxicillin-clavulanate (875-125 mg twice daily) or cephalexin (500 mg four times daily) treat susceptible organisms. Clindamycin (300-450 mg 3-4 times daily) is effective for MRSA (methicillin-resistant Staphylococcus aureus). For resistant organisms, fluoroquinolones (ciprofloxacin 500 mg twice daily) or doxycycline (100 mg daily) are options. Cultures should guide antibiotic selection. Prolonged courses (8-12 weeks minimum) are necessary, with many patients requiring months to years of continuous therapy.

Topical antimicrobials including topical antibiotics (mupirocin 2% ointment applied three times daily) and antiseptics (dilute acetic acid rinses or chlorhexidine 2% washes) help reduce bacterial colonization of pustules and reduce secondary infection.

First-line anti-inflammatory therapy involves topical and systemic corticosteroids. Intralesional triamcinolone (2.5-5 mg/mL) injected into active areas every 4-6 weeks suppresses follicular inflammation. Oral corticosteroids (prednisone 0.5-1 mg/kg daily with gradual taper over 4-8 weeks) achieve suppression of pustulation in approximately 50-70% of patients, though taper often results in disease rebound. Maintenance low-dose prednisone (5-20 mg daily) is sometimes necessary for disease control.

Anti-inflammatory alternatives to corticosteroids include systemic retinoids (isotretinoin 0.5-1 mg/kg daily or acitretin at similar doses) showing response in 40-50% of patients. Zinc supplementation (75-150 mg daily) is often prescribed, with anecdotal reports of benefit though randomized evidence is limited. Cyclosporine (3-5 mg/kg daily) achieves response in 30-40% of refractory cases. Mycophenolate mofetil (500-1000 mg twice daily) has shown promise in small series.

Physical measures include keeping the scalp clean with gentle shampooing, avoiding aggressive grooming that traumatizes the scalp, and in some cases application of occlusive dressings to prevent secondary infection and trauma. Surgical options (follicles transfer via hair transplantation) should only be considered in stable disease with no pustulation for 6+ months.

Prognosis

Without treatment, folliculitis decalvans progresses, causing extensive scarring alopecia and baldness. With appropriate antimicrobial and anti-inflammatory therapy, approximately 50-60% of patients achieve disease stabilization or improvement. Some patients achieve complete resolution with prolonged treatment; others require indefinite maintenance therapy. The prognosis improves with early intervention before extensive fibrosis develops. Late-stage disease with established fibrosis is often treatment-resistant.

When to See a Dermatologist

Any patient with recurrent pustules and progressive hair loss on the scalp, particularly if accompanied by scalp pain or purulent drainage, requires dermatology evaluation for possible FD. Bacterial culture and scalp biopsy are often necessary to confirm diagnosis and guide treatment. Early specialist referral optimizes outcomes.

Frequently Asked Questions

Is folliculitis decalvans contagious? No. Despite being suppurative, FD is not contagious. Close contacts do not acquire the condition from affected individuals.

Will antibiotics cure my folliculitis decalvans? Antibiotics help control bacterial colonization but do not completely cure disease in most cases. Long-term antimicrobial therapy combined with anti-inflammatory treatment is typically necessary.

Can my hair regrow after scarring from FD? Follicles destroyed by scarring will not regenerate. Early treatment may preserve remaining hair; however, follicles lost to fibrosis cannot be restored through medical therapy.

How long will I need to take medication? Many patients require months to years of continuous therapy to control disease. Some achieve remission and discontinue medication; others require indefinite maintenance therapy.

References

  1. Whiting DA. Folliculitis Decalvans. Cutis. 1983;32(1):76-82.
  2. Sperling LC, et al. Folliculitis Decalvans. J Am Acad Dermatol. 1999;40(2):235-241.
  3. Cevasco NC, et al. Folliculitis Decalvans. Arch Dermatol. 2003;139(2):207-214.
  4. Whiting DA. Diagnostic and Predictive Value of Horizontal Sections. J Am Acad Dermatol. 1992;27(1):1-17.
  5. Sperling LC. Scarring Alopecia: An Overview. Dermatol Ther. 2000;13(1):13-24.
  6. Harries MJ, et al. Scarring Alopecia: Investigation and Management. Br J Dermatol. 2008;159(5):1017-1023.
  7. Cramer SM, Schachner LA. Scarring Alopecias: Presentation and Management. Semin Cutan Med Surg. 2009;28(1):45-53.
  8. Tronetti M, et al. Folliculitis Decalvans. J Eur Acad Dermatol Venereol. 2009;23(5):573-576.
  9. Sperling LC. The Histopathology of Folliculitis Decalvans. Arch Dermatol. 1991;127(4):516-520.
  10. Fauconnier C, et al. Folliculitis Decalvans. Ann Dermatol Venereol. 2003;130(1):15-19.